title: Impairing effect of amphetamine and concomitant ionotropic glutamate receptors blockade in the ventral striatum on spatial learning in mice.
abstract: BACKGROUND
  Accumulating evidence supports the involvement of the ventral striatum (VS) in spatial information processing. The multiple cortical glutamatergic and mesolimbic dopaminergic (DAergic) afferences on the same neurons in the ventral striatum provide the neuroanatomical substrate for glutamate and dopamine functional interaction. However, there is little evidence in the literature on how this interaction affects the ability to encode spatial information.
  
  
  OBJECTIVE
  First, we evaluated the effect of intra-VS bilateral infusion of different doses of amphetamine (0.3, 0.75, and 1.5 μg/side) on the ability to detect spatial novelty in mice. Next, we examined the impact produced on the same abilities by intra-VS infusion of ineffective doses of amphetamine (0.3 μg/side) in association with N-methyl-D-aspartate (NMDA) (3.125 ng/side) or α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) (0.25 ng/side) receptor antagonist.
  
  
  RESULTS
  The results show that infusion of amphetamine impairs detection of spatial novelty, affecting also exploratory activity and marginally the detection of nonspatial novelty. In contrast, an association of subthreshold doses of amphetamine with NMDA or AMPA receptor antagonists exerted a selective effect on reactivity to a spatial change.
  
  
  CONCLUSIONS
  These findings demonstrate that enhanced DAergic activity in the VS enhances glutamate receptor antagonist-induced impairment in learning and memory.
authors: Department of Biology and Biotechnology, Università degli Studi di Roma "La Sapienza", P.le Aldo Moro 5, 00185 Rome, Italy.
authors: Roberto
authors: R
authors: Coccurello
authors: Alberto
authors: A
authors: Oliverio
authors: Andrea
authors: A
authors: Mele
mesh_terms: D015763:2-Amino-5-phosphonovalerate / Q000008:administration & dosage / Q000494:pharmacology; D000661:Amphetamine / Q000008:administration & dosage / Q000633:toxicity*; D000818:Animals; D001479:Basal Ganglia / Q000187:drug effects / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005106:Exploratory Behavior / Q000187:drug effects*; D008297:Male; D051379:Mice; D011810:Quinoxalines / Q000008:administration & dosage / Q000494:pharmacology; D018091:Receptors, AMPA / Q000037:antagonists & inhibitors*; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*
chemical_list: D011810:Quinoxalines; D018091:Receptors, AMPA; D016194:Receptors, N-Methyl-D-Aspartate; D015763:2-Amino-5-phosphonovalerate; D000661:Amphetamine; D004298:Dopamine
references: Behav Neurosci. 1998 Jun;112(3):603-10
references: 9676976
references: BMC Neurosci. 2006 Jun 30;7:53
references: 16813648
references: J Comp Neurol. 1994 Jun 1;344(1):1-19
references: 7914894
references: Eur J Neurosci. 2004 May;19(9):2455-63
references: 15128399
references: Behav Brain Res. 1989 Jan 1;31(3):231-42
references: 2914074
references: J Neurosci. 2001 Mar 15;21(6):2143-9
references: 11245698
references: Behav Brain Res. 1989 Apr 1;32(3):265-77
references: 2496702
references: Learn Mem. 2008 Dec 30;16(1):46-52
references: 19117916
references: Brain Res. 1984 Jun 8;302(2):267-75
references: 6145508
references: J Neurosci. 2000 Oct 15;20(20):7737-42
references: 11027236
references: J Neural Transm Gen Sect. 1995;101(1-3):127-48
references: 8695043
references: Psychopharmacology (Berl). 1998 May;137(2):175-83
references: 9630004
references: Learn Mem. 2005 Sep-Oct;12(5):491-503
references: 16166396
references: J Psychiatry Neurosci. 2007 Nov;32(6):400-11
references: 18043763
references: J Neurosci. 2008 Jul 2;28(27):6950-9
references: 18596169
references: Behav Brain Res. 1996 Nov;81(1-2):163-71
references: 8950013
references: Psychopharmacology (Berl). 2000 Oct;152(2):189-99
references: 11057523
references: Annu Rev Neurosci. 2000;23:185-215
references: 10845063
references: Psychopharmacology (Berl). 1994 Aug;115(4):516-28
references: 7871097
references: Ann N Y Acad Sci. 1999 Jun 29;877:49-63
references: 10415642
references: Proc Natl Acad Sci U S A. 1993 Oct 15;90(20):9576-80
references: 7692449
references: J Neural Transm Gen Sect. 1992;88(3):235-40
references: 1358121
references: Trends Neurosci. 1990 Jul;13(7):259-65
references: 1695400
references: Prog Neurobiol. 1980;14(2-3):69-97
references: 6999537
references: Behav Neurosci. 1999 Aug;113(4):703-17
references: 10495079
references: Neurosci Res. 1997 Jan;27(1):1-8
references: 9089693
references: J Neurocytol. 1996 Dec;25(12):843-56
references: 9023729
references: J Neurophysiol. 2002 Dec;88(6):3010-20
references: 12466426
references: Learn Mem. 2005 May-Jun;12(3):285-95
references: 15930507
references: Neurosci Biobehav Rev. 2004 Jan;27(8):765-76
references: 15019426
references: Brain Res Brain Res Rev. 1999 Dec;31(1):6-41
references: 10611493
references: Behav Pharmacol. 1995 Aug;6(5 And 6):527-539
references: 11224360
references: Psychopharmacology (Berl). 2005 Apr;179(1):108-16
references: 15682297
references: Neuropsychopharmacology. 2012 Apr;37(5):1122-33
references: 22218092
references: Synapse. 1996 Sep;24(1):65-78
references: 9046078
references: Ann N Y Acad Sci. 2003 Nov;1003:36-52
references: 14684434
references: Dev Neurosci. 1998;20(1):1-18
references: 9600386
references: Neuron. 2004 May 27;42(4):653-63
references: 15157425
references: Behav Processes. 1992;26(1):43-57
references: 24924208
references: Neuroscience. 2004;128(2):229-38
references: 15350636
references: Nat Neurosci. 2000 Mar;3(3):226-30
references: 10700253